News Headlines Article

Two Bay Area drug companies cut half-billion-dollar cancer drug deal
San Francisco Business Times

A cancer-fighting drug that BioMarin Pharmaceutical Inc. picked up in a $97 million acquisition five years ago is at the center of a potential $570 million deal with fellow Bay Area drug developer Medivation Inc. The late-stage drug — dubbed talazoparib, or BMN-673 — is a so-called PARP inhibitor, a class of drugs that block enzymes that cancer cells use to repair themselves after chemotherapy or other stresses.